

Ricky w Johnstone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/982939/publications.pdf>

Version: 2024-02-01

255
papers

30,768
citations

5261

83
h-index

4770

169
g-index

270
all docs

270
docs citations

270
times ranked

37987
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer activities of histone deacetylase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 769-784.	21.5	2,578
2	Apoptosis. <i>Cell</i> , 2002, 108, 153-164.	13.5	2,122
3	Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 287-299.	21.5	1,335
4	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 673-691.	21.5	1,277
5	New and emerging HDAC inhibitors for cancer treatment. <i>Journal of Clinical Investigation</i> , 2014, 124, 30-39.	3.9	1,137
6	The TRAIL apoptotic pathway in cancer onset, progression and therapy. <i>Nature Reviews Cancer</i> , 2008, 8, 782-798.	12.8	788
7	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19512-19517.	3.3	611
8	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3697-3702.	3.3	504
9	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10833-10838.	3.3	468
10	Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. <i>Cancer Cell</i> , 2012, 22, 51-65.	7.7	468
11	Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor. <i>Immunity</i> , 2012, 36, 561-571.	6.6	456
12	Histone deacetylase inhibitors in cancer therapy. <i>Cancer Cell</i> , 2003, 4, 13-18.	7.7	451
13	BET inhibitor resistance emerges from leukaemia stem cells. <i>Nature</i> , 2015, 525, 538-542.	13.7	441
14	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	2.1	437
15	Epigenetics in cancer: Targeting chromatin modifications. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1409-1420.	1.9	435
16	Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling. <i>Immunity</i> , 2012, 36, 166-174.	6.6	372
17	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 5341.	5.8	356
18	Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme B-Mediated Caspase Activation. <i>Journal of Experimental Medicine</i> , 2000, 192, 1403-1414.	4.2	331

#	ARTICLE	IF	CITATIONS
19	The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7024-7029.	3.3	328
20	Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends in Biochemical Sciences, 2000, 25, 1-6.	3.7	301
21	IFN β signaling—Does it mean JAK—STAT?. Cytokine and Growth Factor Reviews, 2008, 19, 383-394.	3.2	292
22	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. Blood, 1999, 93, 1075-1085.	0.6	288
23	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research, 2008, 14, 4500-4510.	3.2	286
24	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.4	270
25	Targeting the epigenetic regulation of antitumour immunity. Nature Reviews Drug Discovery, 2020, 19, 776-800.	21.5	264
26	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	3.9	251
27	Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies. Cancer Research, 2012, 72, 3163-3174.	0.4	248
28	A Novel Repressor, par-4, Modulates Transcription and Growth Suppression Functions of the Wilms TM Tumor Suppressor WT1. Molecular and Cellular Biology, 1996, 16, 6945-6956.	1.1	246
29	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	2.9	244
30	Tumor immune evasion arises through loss of TNF sensitivity. Science Immunology, 2018, 3, .	5.6	244
31	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	7.7	242
32	Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene, 1997, 15, 453-457.	2.6	238
33	Rational Combinations Using HDAC Inhibitors. Clinical Cancer Research, 2009, 15, 3970-3977.	3.2	207
34	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters, 2009, 280, 125-133.	3.2	199
35	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	3.3	195
36	Histone deacetylase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2007, 16, 659-678.	1.9	193

#	ARTICLE	IF	CITATIONS
37	Expression and Function of the Leucine Zipper Protein Par-4 in Apoptosis. <i>Molecular and Cellular Biology</i> , 1997, 17, 3823-3832.	1.1	191
38	The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest. <i>Cell</i> , 2007, 129, 423-433.	13.5	189
39	Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. <i>Oncogene</i> , 2005, 24, 8061-8075.	2.6	184
40	Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. <i>Cancer Research</i> , 2003, 63, 4460-71.	0.4	183
41	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. <i>Nature</i> , 2018, 560, 253-257.	13.7	182
42	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. <i>Blood</i> , 2012, 120, 376-385.	0.6	174
43	An activating <i>Pik3ca</i> mutation coupled with <i>Pten</i> loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 553-557.	3.9	174
44	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016, 538, 518-522.	13.7	159
45	The HIN-200 family: More than interferon-inducible genes?. <i>Experimental Cell Research</i> , 2005, 308, 1-17.	1.2	152
46	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013, 4, e519-e519.	2.7	150
47	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. <i>Science Translational Medicine</i> , 2016, 8, 339ra69.	5.8	140
48	Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1. <i>PLoS Biology</i> , 2010, 8, e1000361.	2.6	134
49	Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. <i>Oncogene</i> , 2004, 23, 6693-6701.	2.6	129
50	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11317-11322.	3.3	129
51	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. <i>Blood</i> , 2011, 117, 3658-3668.	0.6	128
52	Histone-Deacetylase Inhibitors for the Treatment of Cancer. <i>Cell Cycle</i> , 2004, 3, 777-786.	1.3	127
53	Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. <i>Oncogene</i> , 2012, 31, 1661-1672.	2.6	127
54	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. <i>Science Signaling</i> , 2011, 4, ra56.	1.6	126

#	ARTICLE	IF	CITATIONS
55	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e387-e390.	1.7	124
56	Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. <i>Investigational New Drugs</i> , 2010, 28, 3-20.	1.2	123
57	CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. <i>Leukemia</i> , 2015, 29, 1437-1441.	3.3	120
58	Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. <i>Future Oncology</i> , 2009, 5, 601-612.	1.1	119
59	Asymmetric Cell Division of T Cells upon Antigen Presentation Uses Multiple Conserved Mechanisms. <i>Journal of Immunology</i> , 2010, 185, 367-375.	0.4	117
60	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. <i>Cell Reports</i> , 2013, 5, 1047-1059.	2.9	116
61	Transcription and Growth Regulatory Functions of the HIN-200 Family of Proteins. <i>Molecular and Cellular Biology</i> , 1999, 19, 5833-5838.	1.1	115
62	Human Immunodeficiency Virus Type 1 Nef Binds to Tumor Suppressor p53 and Protects Cells against p53-Mediated Apoptosis. <i>Journal of Virology</i> , 2002, 76, 2692-2702.	1.5	113
63	An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. <i>Cancer Research</i> , 2013, 73, 7265-7276.	0.4	112
64	A Central Role for Bid in Granzyme B-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2005, 280, 4476-4482.	1.6	111
65	A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. <i>Oncogene</i> , 2003, 22, 8931-8938.	2.6	108
66	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. <i>Blood</i> , 2009, 114, 380-393.	0.6	108
67	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. <i>Blood</i> , 2014, 123, 1341-1352.	0.6	107
68	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. <i>Blood</i> , 2013, 121, 3459-3468.	0.6	106
69	A Role for P-Glycoprotein in Regulating Cell Death. <i>Leukemia and Lymphoma</i> , 2000, 38, 1-11.	0.6	105
70	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 59-70.	7.7	105
71	Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. <i>Oncogene</i> , 2003, 22, 4831-4840.	2.6	104
72	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021, 184, 3143-3162.e32.	13.5	103

#	ARTICLE	IF	CITATIONS
73	Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity. <i>Advances in Cancer Research</i> , 2012, 116, 165-197.	1.9	101
74	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016, 76, 1158-1169.	0.4	100
75	Oncogenes in Cell Survival and Cell Death. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a009829-a009829.	2.3	99
76	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4141-4146.	3.3	98
77	How do tumor cells respond to HDAC inhibition?. <i>FEBS Journal</i> , 2016, 283, 4032-4046.	2.2	97
78	Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. <i>Molecular Immunology</i> , 1993, 30, 1231-1241.	1.0	95
79	Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. <i>Oncogene</i> , 2000, 19, 6033-6042.	2.6	95
80	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017, 23, 2478-2490.	3.2	95
81	Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. <i>Cell Death and Differentiation</i> , 2004, 11, 1028-1037.	5.0	93
82	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016, 29, 145-158.	7.7	93
83	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. <i>Oncotarget</i> , 2016, 7, 49800-49818.	0.8	93
84	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	3.6	92
85	Histone deacetylase inhibitors in lymphoma and solid malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 413-432.	1.1	89
86	Identification and quantification of complement regulator CD46 on normal human tissues. <i>Immunology</i> , 1993, 79, 341-7.	2.0	88
87	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011, 118, 6274-6283.	0.6	83
88	Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2-Deoxycytidine in Solid Tumor Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2226-2236.	1.9	81
89	Filamin (280-kDa Actin-binding Protein) Is a Caspase Substrate and Is Also Cleaved Directly by the Cytotoxic T Lymphocyte Protease Granzyme B during Apoptosis. <i>Journal of Biological Chemistry</i> , 2000, 275, 39262-39266.	1.6	79
90	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. <i>Nature Medicine</i> , 2014, 20, 283-290.	15.2	79

#	ARTICLE	IF	CITATIONS
91	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020, 6, .	4.7	79
92	From cancer immunosurveillance to cancer immunotherapy. <i>Immunological Reviews</i> , 2007, 220, 82-101.	2.8	78
93	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019, 28, 2784-2794.e5.	2.9	77
94	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000, 95, 2378-2385.	0.6	76
95	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017, 17, 160-183.	12.8	76
96	Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. <i>Bioinformatics</i> , 2014, 30, 1064-1072.	1.8	75
97	P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. <i>Cell Death and Differentiation</i> , 2002, 9, 1266-1272.	5.0	74
98	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. <i>Oncogene</i> , 2013, 32, 4191-4202.	2.6	74
99	The anticancer effects of HDAC inhibitors require the immune system. <i>Oncolmmunology</i> , 2014, 3, e27414.	2.1	74
100	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. <i>Blood</i> , 2017, 129, 2882-2895.	0.6	74
101	Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. <i>Blood</i> , 2009, 113, 1982-1991.	0.6	73
102	Manipulation of B-cell responses with histone deacetylase inhibitors. <i>Nature Communications</i> , 2015, 6, 6838.	5.8	73
103	The Human Interferon-inducible Protein, IFI 16, Is a Repressor of Transcription. <i>Journal of Biological Chemistry</i> , 1998, 273, 17172-17177.	1.6	72
104	Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. <i>International Journal of Cancer</i> , 2002, 99, 292-298.	2.3	72
105	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , 2013, 49, 3936-3944.	1.3	72
106	<i>In Vivo</i> Activity of Combined PI3K/mTOR and MEK Inhibition in a <i>KrasG12D</i> ; <i>Pten</i> Deletion Mouse Model of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1440-1449.	1.9	70
107	SnapShot: Extrinsic Apoptosis Pathways. <i>Cell</i> , 2010, 143, 1192-1192.e2.	13.5	68
108	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019, 7, 183-192.	1.6	68

#	ARTICLE	IF	CITATIONS
109	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. <i>Blood</i> , 2012, 120, 3019-3029.	0.6	67
110	Identification, Cloning, Expression, and Biochemical Characterization of the Testis-specific RNA Polymerase II Elongation Factor ELL3. <i>Journal of Biological Chemistry</i> , 2000, 275, 32052-32056.	1.6	66
111	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
112	The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. <i>Molecular Immunology</i> , 1990, 27, 327-333.	1.0	64
113	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. <i>Molecular and Cellular Biology</i> , 2003, 23, 6520-6532.	1.1	64
114	Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1066-1079.	1.9	63
115	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021, 11, 2582-2601.	7.7	62
116	Ciao 1 Is a Novel WD40 Protein That Interacts with the Tumor Suppressor Protein WT1. <i>Journal of Biological Chemistry</i> , 1998, 273, 10880-10887.	1.6	60
117	PIDDosome-independent tumor suppression by Caspase-2. <i>Cell Death and Differentiation</i> , 2012, 19, 1722-1732.	5.0	60
118	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2019, 25, 258-272.e9.	5.2	60
119	Expression of IFI16 in epithelial cells and lymphoid tissues. <i>Histochemistry and Cell Biology</i> , 2003, 119, 45-54.	0.8	59
120	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. <i>Blood</i> , 2013, 121, 2964-2974.	0.6	59
121	Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. <i>Blood</i> , 2014, 123, 725-733.	0.6	59
122	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	4.5	59
123	Targeting transcription cycles in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 5-24.	12.8	59
124	The mTORC1 Inhibitor Everolimus Prevents and Treats $\frac{1}{4}$ -Myc Lymphoma by Restoring Oncogene-Induced Senescence. <i>Cancer Discovery</i> , 2013, 3, 82-95.	7.7	58
125	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2030-2041.	1.9	57
126	Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors. <i>PLoS ONE</i> , 2009, 4, e4482.	1.1	57

#	ARTICLE	IF	CITATIONS
127	Isotypic Variants of the Interferon-Inducible Transcriptional Repressor IFI 16 Arise through Differential mRNA Splicing. <i>Biochemistry</i> , 1998, 37, 11924-11931.	1.2	55
128	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. <i>Leukemia</i> , 2020, 34, 1646-1657.	3.3	54
129	A Novel c-Jun-dependent Signal Transduction Pathway Necessary for the Transcriptional Activation of Interferon β Response Genes. <i>Journal of Biological Chemistry</i> , 2007, 282, 938-946.	1.6	52
130	Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. <i>Cell Death and Differentiation</i> , 2017, 24, 961-970.	5.0	52
131	Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737. <i>Cancer Research</i> , 2011, 71, 3603-3615.	0.4	51
132	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012, 120, 822-832.	0.6	50
133	Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. <i>Journal of Neuroimmunology</i> , 1992, 36, 199-208.	1.1	49
134	Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. <i>Transplant Immunology</i> , 1993, 1, 101-108.	0.6	49
135	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020, 28, 2379-2393.	3.7	49
136	Mapping of the Human PAWR (par-4) Gene to Chromosome 12q21. <i>Genomics</i> , 1998, 53, 241-243.	1.3	48
137	Role of TNF in lymphocyte-mediated cytotoxicity. <i>Microscopy Research and Technique</i> , 2000, 50, 196-208.	1.2	48
138	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. <i>Blood</i> , 2015, 126, 2392-2403.	0.6	48
139	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. <i>Science Advances</i> , 2021, 7, .	4.7	46
140	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16254-16259.	3.3	45
141	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2709-2721.	1.9	45
142	Novel properties of the protein kinase CK2-site-regulated nuclear-localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2001, 353, 69-77.	1.7	44
143	The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the E μ 4-myc model of B-cell lymphoma. <i>Oncogene</i> , 2014, 33, 5415-5423.	2.6	43
144	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. <i>Cell Death and Disease</i> , 2012, 3, e409-e409.	2.7	42

#	ARTICLE	IF	CITATIONS
145	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020, 26, 6535-6549.	3.2	42
146	Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 417-424.	1.0	41
147	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. <i>Nature Communications</i> , 2019, 10, 1347.	5.8	41
148	Histone-deacetylase inhibitors for the treatment of cancer. <i>Cell Cycle</i> , 2004, 3, 779-88.	1.3	41
149	Perforin-mediated suppression of B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2723-2728.	3.3	40
150	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. <i>Journal of Immunology</i> , 2020, 204, 2308-2315.	0.4	40
151	Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 965-969.	1.2	39
152	A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax [®]). <i>Epigenomics</i> , 2012, 4, 571-589.	1.0	39
153	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1439-1449.	1.1	38
154	The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. <i>Journal of Leukocyte Biology</i> , 1998, 64, 546-554.	1.5	37
155	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. <i>Cell Reports</i> , 2016, 14, 1858-1866.	2.9	35
156	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1582-1599.	7.7	35
157	Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. <i>Cell Death and Differentiation</i> , 2008, 15, 708-717.	5.0	34
158	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. <i>Cell Reports</i> , 2014, 7, 1009-1019.	2.9	34
159	Functional Analysis of the Leukemia Protein ELL: Evidence for a Role in the Regulation of Cell Growth and Survival. <i>Molecular and Cellular Biology</i> , 2001, 21, 1672-1681.	1.1	33
160	Genomic characterisation of E14-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. <i>Nature Communications</i> , 2017, 8, 14581.	5.8	33
161	Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. <i>Journal of Immunology</i> , 1999, 163, 1350-3.	0.4	33
162	Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. <i>Cell Death and Disease</i> , 2013, 4, e798-e798.	2.7	32

#	ARTICLE	IF	CITATIONS
163	Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity. <i>FEBS Journal</i> , 2016, 283, 947-961.	2.2	31
164	The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. <i>Radiation Research</i> , 2014, 182, 219.	0.7	29
165	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2016, 30, 59-74.	7.7	29
166	P-glycoprotein Does Not Protect Cells against Cytolysis Induced by Pore-forming Proteins. <i>Journal of Biological Chemistry</i> , 2001, 276, 16667-16673.	1.6	26
167	From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma. <i>Cancer Cell</i> , 2014, 25, 9-11.	7.7	26
168	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. <i>Cancer Research</i> , 2016, 76, 3965-3977.	0.4	26
169	Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 237-241.	3.3	26
170	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. <i>Genes and Development</i> , 2018, 32, 849-864.	2.7	26
171	Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress. <i>Current Cancer Drug Targets</i> , 2002, 2, 337-353.	0.8	25
172	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. <i>Leukemia</i> , 2017, 31, 1466-1470.	3.3	25
173	HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. <i>Blood</i> , 2000, 95, 2378-2385.	0.6	25
174	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. <i>Oncogenesis</i> , 2016, 5, e216-e216.	2.1	24
175	Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 3388-3392.	3.3	24
176	Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI 16. <i>Journal of Cellular Biochemistry</i> , 2003, 89, 80-93.	1.2	23
177	Id2 represses E2A-mediated activation of IL-10 expression in T cells. <i>Blood</i> , 2014, 123, 3420-3428.	0.6	23
178	HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors. <i>Cancer Research</i> , 2017, 77, 2594-2606.	0.4	23
179	Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8 ⁺ Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 1998, 72, 5948-5954.	1.5	23
180	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH ⁺ MYCN neuroblastoma mouse model. <i>International Journal of Cancer</i> , 2016, 139, 194-204.	2.3	22

#	ARTICLE	IF	CITATIONS
181	HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. <i>Leukemia</i> , 2017, 31, 995-997.	3.3	22
182	Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 502-514.	0.4	22
183	Strong associations between RFLP and protein polymorphisms for CD46. <i>Immunogenetics</i> , 1992, 36, 79-85.	1.2	21
184	Promises and challenges of anticancer drugs that target the epigenome. <i>Epigenomics</i> , 2011, 3, 547-565.	1.0	21
185	Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. <i>Cell Death and Disease</i> , 2018, 9, 442.	2.7	20
186	Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. <i>Nature Communications</i> , 2021, 12, 2782.	5.8	20
187	<i>AKT</i> signalling is required for ribosomal <i>RNA</i> synthesis and progression of <i>E₁₄-Myc B-cell lymphoma</i> <i>in vivo</i> . <i>FEBS Journal</i> , 2013, 280, 5307-5316. ^{2,2}		19
188	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. <i>Blood</i> , 2021, 137, 2947-2957.	0.6	19
189	Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. <i>Cell Death and Disease</i> , 2012, 3, e344-e344.	2.7	18
190	DOCK8 Drives Src-Dependent NK Cell Effector Function. <i>Journal of Immunology</i> , 2017, 199, 2118-2127.	0.4	18
191	Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). <i>Cancer Research</i> , 1990, 50, 5225-30.	0.4	18
192	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6222-6234.	3.2	17
193	Lethal Giant Larvae 1 Tumour Suppressor Activity Is Not Conserved in Models of Mammalian T and B Cell Leukaemia. <i>PLoS ONE</i> , 2014, 9, e87376.	1.1	17
194	P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. <i>Blood</i> , 1999, 93, 1075-1085.	0.6	16
195	A functional genomics screen identifies PCAF and ADA3 as regulators of human granzyme B-mediated apoptosis and Bid cleavage. <i>Cell Death and Differentiation</i> , 2014, 21, 748-760.	5.0	15
196	Scribble acts as an oncogene in <i>E₁₄-myc</i> -driven lymphoma. <i>Oncogene</i> , 2016, 35, 1193-1197.	2.6	15
197	Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice. <i>Cancer Research</i> , 1990, 50, 4423-8.	0.4	15
198	A role for P-glycoprotein in regulating cell growth and survival. <i>Clinical and Applied Immunology Reviews</i> , 2003, 4, 31-47.	0.4	14

#	ARTICLE	IF	CITATIONS
199	Response: Does Bid Play a Role in the DNA Damage Response?. <i>Cell</i> , 2007, 130, 10-11.	13.5	14
200	The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. <i>Oncolmmunology</i> , 2012, 1, 377-379.	2.1	14
201	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. <i>Leukemia Research</i> , 2014, 38, 948-954.	0.4	14
202	Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. <i>Scientific Data</i> , 2014, 1, 140017.	2.4	14
203	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 4338-4352.	3.2	14
204	Equivalent Death of P-Glycoprotein Expressing and Nonexpressing Cells Induced by the Protein Kinase C Inhibitor Staurosporine. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 231-237.	1.0	13
205	Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 103-112.	1.2	13
206	MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). <i>Annals of Hematology</i> , 2011, 90, 847-849.	0.8	13
207	Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. <i>Oncolmmunology</i> , 2012, 1, 1629-1631.	2.1	13
208	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 2.	1.8	13
209	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. <i>Oncotarget</i> , 2016, 7, 34582-34598.	0.8	13
210	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	7.7	13
211	A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. <i>Cell Death and Differentiation</i> , 2016, 23, 1209-1218.	5.0	12
212	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , 2017, 58, 996-998.	0.6	12
213	The Role of p202 in Regulating Hematopoietic Cell Proliferation and Differentiation. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 5-11.	0.5	11
214	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011, 128, 2735-2747.	2.3	11
215	Modulation of antitumour immune responses by intratumoural Stat1 expression. <i>Immunology and Cell Biology</i> , 2013, 91, 556-567.	1.0	11
216	Functional characterisation of alternatively spliced CD46 cytoplasmic tails. <i>Transplantation Proceedings</i> , 1992, 24, 2329-30.	0.3	11

#	ARTICLE	IF	CITATIONS
217	Identification of four different CD46 (MCP) molecules with anti-peptide antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1991, 180, 1091-1097.	1.0	10
218	Regulating the TRAIL of Destruction: How A20 Protects Glioblastomas from TRAIL-Mediated Death: Figure 1.. <i>Cancer Discovery</i> , 2012, 2, 112-114.	7.7	10
219	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e15203.	3.3	10
220	Cloning and characterisation of <i>HIN-200</i> : A new murine HIN-200 family member. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1270-1282.	1.2	9
221	Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors. <i>Cell Death and Disease</i> , 2012, 3, e387-e387.	2.7	9
222	Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide. <i>Thrombosis Research</i> , 2013, 131, 514-520.	0.8	9
223	Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Aesthetic Surgery Journal</i> , 2016, 36, 782-783.	0.9	9
224	Deamidation of Bcl-XL. <i>Molecular Cell</i> , 2002, 10, 695-697.	4.5	8
225	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014, 21, 297-308.	1.2	8
226	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 87-107.	1.6	8
227	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
228	Novel properties of the protein kinase CK2-site-regulated nuclear-localization sequence of the interferon-induced nuclear factor IFI 16. <i>Biochemical Journal</i> , 2000, 353, 69.	1.7	7
229	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	1.7	7
230	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. <i>Haematologica</i> , 2021, 106, 2013-2017.	1.7	7
231	The multidrug resistance gene <i>mdr1a</i> influences resistance to ectromelia virus infection by mechanisms other than conventional immunity. <i>Immunology and Cell Biology</i> , 2004, 82, 462-470.	1.0	6
232	Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. <i>Transplantation Proceedings</i> , 1994, 26, 1070-1.	0.3	6
233	Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis. <i>Cell Death and Differentiation</i> , 2022, 29, 2519-2530.	5.0	5
234	A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. <i>Methods in Molecular Biology</i> , 2018, 1725, 201-227.	0.4	4

#	ARTICLE	IF	CITATIONS
235	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020, 33, 108290.	2.9	4
236	MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. <i>Blood Advances</i> , 2020, 4, 4918-4923.	2.5	4
237	Tissue-specific expression of CD46 isoforms. <i>Transplantation Proceedings</i> , 1992, 24, 2331-2.	0.3	4
238	CD46 (MCP) confers protection from lysis by xenogeneic antibodies. <i>Transplantation Proceedings</i> , 1993, 25, 396-7.	0.3	4
239	Dissecting the apoptotic mechanisms of chemotherapeutic drugs and lymphocytes to design effective anticancer therapies. <i>Drug Development Research</i> , 2001, 52, 549-557.	1.4	3
240	Molecular characterization of the polymorphic expression of CD46: a cell surface molecule protecting cells from complement attack. <i>Transplantation Proceedings</i> , 1992, 24, 211-3.	0.3	3
241	Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. <i>Leukemia</i> , 2012, 26, 1433-1435.	3.3	2
242	Letter to the Editor, "BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction". <i>Journal of Dental Research</i> , 2015, 94, 229-229.	2.5	2
243	Constitutive IFN γ /IFN β signaling maintains expression of signaling intermediaries for efficient cytokine responses. <i>Jak-stat</i> , 2016, 5, e1173804.	2.2	2
244	Suberanilohydroxamic Acid. Aton Pharma. <i>IDrugs: the Investigational Drugs Journal</i> , 2004, 7, 674-82.	0.7	2
245	Structural organization, tissue expression, and chromosomal localization of Ciao 1, a functional modulator of the Wilms' tumor suppressor, WT1. <i>Immunogenetics</i> , 1999, 49, 900-905.	1.2	1
246	In the Midst of Life "Cell Death: What Is It, What Is It Good for, and How to Study It. <i>Cold Spring Harbor Protocols</i> , 2016, 2016, pdb.top070508.	0.2	1
247	The question begs "what is the role of P-glycoprotein in normal physiology?". <i>Drug Resistance Updates</i> , 1998, 1, 340-342.	6.5	0
248	P-glycoprotein as a General Antiapoptotic Protein. , 2002, , 433-441.		0
249	Development of targeted therapies for acute myeloid leukemias. <i>Experimental Hematology</i> , 2013, 41, S49.	0.2	0
250	Cyclin-dependent kinase inhibitor, dinaciclib induces anti-tumour activity of MLL-AF9 in vivo mouse models. <i>Experimental Hematology</i> , 2013, 41, S53.	0.2	0
251	Joseph F. Sambrook (1939-2019). <i>Nature Structural and Molecular Biology</i> , 2019, 26, 846-847.	3.6	0
252	Wilms Tumor Suppressor WT1. , 2002, , 543-551.		0

#	ARTICLE	IF	CITATIONS
253	Growth Suppressors IFI-204 and IFI-205 Inhibit Primitive Hematopoietic Cell Proliferation In Vitro and in Vivo.. Blood, 2004, 104, 1691-1691.	0.6	0
254	Epigenetic Drugs. , 2008, , 49-71.		0
255	Epigenetic Drugs Histone Deacetylase Inhibitors. , 2008, , 49-71.		0